SG11201810531TA - Ligand identification by co-fractionation - Google Patents
Ligand identification by co-fractionationInfo
- Publication number
- SG11201810531TA SG11201810531TA SG11201810531TA SG11201810531TA SG11201810531TA SG 11201810531T A SG11201810531T A SG 11201810531TA SG 11201810531T A SG11201810531T A SG 11201810531TA SG 11201810531T A SG11201810531T A SG 11201810531TA SG 11201810531T A SG11201810531T A SG 11201810531TA
- Authority
- SG
- Singapore
- Prior art keywords
- ligands
- international
- potsdam
- macromolecules
- pct
- Prior art date
Links
- 239000003446 ligand Substances 0.000 title abstract 9
- 238000005194 fractionation Methods 0.000 title abstract 3
- 229920002521 macromolecule Polymers 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 239000011534 wash buffer Substances 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 101100172879 Caenorhabditis elegans sec-5 gene Proteins 0.000 abstract 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 abstract 1
- 238000009614 chemical analysis method Methods 0.000 abstract 1
- 230000009089 cytolysis Effects 0.000 abstract 1
- 238000001914 filtration Methods 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000008188 pellet Substances 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
- G01N33/537—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/34—Purifying; Cleaning
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N24/00—Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects
- G01N24/08—Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects by using nuclear magnetic resonance
- G01N24/087—Structure determination of a chemical compound, e.g. of a biomolecule such as a protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N24/00—Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects
- G01N24/08—Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects by using nuclear magnetic resonance
- G01N24/088—Assessment or manipulation of a chemical or biochemical reaction, e.g. verification whether a chemical reaction occurred or whether a ligand binds to a receptor in drug screening or assessing reaction kinetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/62—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating the ionisation of gases, e.g. aerosols; by investigating electric discharges, e.g. emission of cathode
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6848—Methods of protein analysis involving mass spectrometry
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- High Energy & Nuclear Physics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rehabilitation Therapy (AREA)
- Rheumatology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Electrochemistry (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16172000 | 2016-05-30 | ||
| PCT/EP2017/062841 WO2017207460A1 (en) | 2016-05-30 | 2017-05-29 | Ligand identification by co-fractionation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201810531TA true SG11201810531TA (en) | 2018-12-28 |
Family
ID=56119308
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201810531TA SG11201810531TA (en) | 2016-05-30 | 2017-05-29 | Ligand identification by co-fractionation |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US10976310B2 (da) |
| EP (1) | EP3465207B1 (da) |
| KR (1) | KR102346785B1 (da) |
| CN (1) | CN109219750B (da) |
| AU (1) | AU2017272493B2 (da) |
| BR (1) | BR112018074856A2 (da) |
| DK (1) | DK3465207T3 (da) |
| ES (1) | ES2899110T3 (da) |
| HU (1) | HUE056359T2 (da) |
| LT (1) | LT3465207T (da) |
| PL (1) | PL3465207T3 (da) |
| PT (1) | PT3465207T (da) |
| SG (1) | SG11201810531TA (da) |
| SI (1) | SI3465207T1 (da) |
| WO (1) | WO2017207460A1 (da) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113196055B (zh) | 2018-10-15 | 2025-06-27 | 马克斯·普朗克科学促进协会 | 用于治疗疾病的化合物及其筛选方法 |
| CA3127237A1 (en) | 2019-02-08 | 2020-08-13 | Dewpoint Therapeutics, Inc. | Methods of characterizing condensate-associated characteristics of compounds and uses thereof |
| KR20220084047A (ko) | 2019-09-18 | 2022-06-21 | 듀포인트 테라퓨틱스, 인크. | 응축물 관련 특이성에 대한 스크리닝 방법 및 이의 용도 |
| JP7327096B2 (ja) * | 2019-11-13 | 2023-08-16 | 株式会社島津製作所 | 分子の分離方法 |
| IL295143B2 (en) * | 2020-02-13 | 2026-02-01 | Hoffmann La Roche | A method for determining the loading state of AAV particles using nuclear magnetic resonance relaxometry |
| CN113528497B (zh) * | 2021-07-22 | 2022-06-24 | 中国林业科学研究院林业研究所 | Fba8基因或fba8蛋白在制备具有磷酸转移活性和/或蛋白水解活性的试剂中的应用 |
| CN120303045A (zh) * | 2022-11-26 | 2025-07-11 | 恩维达治疗公司 | 用于鉴定形成、稳定或破坏分子复合物的化合物的方法和系统 |
| CN118685492A (zh) * | 2024-03-08 | 2024-09-24 | 西湖实验室(生命科学和生物医学浙江省实验室) | 微量新鲜样本六组学连续提取方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4459359A (en) | 1981-11-19 | 1984-07-10 | New York Blood Center, Inc. | Sensitive immunoassays of antigens or antibodies sequestered within immune complexes |
| AU774776B2 (en) * | 1999-04-15 | 2004-07-08 | University Of Virginia Patent Foundation | Proteome mining |
| CN1658892A (zh) | 2002-08-14 | 2005-08-24 | 布朗歇特洛克菲勒神经科学研究所 | 参与蛋白质－蛋白质相互作用的蛋白质亚群的分离方法 |
| WO2006015796A1 (en) * | 2004-08-09 | 2006-02-16 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Method for high-throughput screening of test molecules binding to target molecules |
| US20150105280A1 (en) | 2010-03-10 | 2015-04-16 | Perfinity Biosciences, Inc. | Selector based recognition and quantification system and method for multiple analytes in a single analysis |
| EP2922861A4 (en) * | 2012-11-26 | 2016-09-14 | Caris Life Sciences Switzerland Holdings Gmbh | BIOMARKER COMPOSITIONS AND METHODS |
-
2017
- 2017-05-29 CN CN201780034328.7A patent/CN109219750B/zh active Active
- 2017-05-29 SI SI201730986T patent/SI3465207T1/sl unknown
- 2017-05-29 DK DK17725620.3T patent/DK3465207T3/da active
- 2017-05-29 EP EP17725620.3A patent/EP3465207B1/en active Active
- 2017-05-29 KR KR1020187038204A patent/KR102346785B1/ko active Active
- 2017-05-29 WO PCT/EP2017/062841 patent/WO2017207460A1/en not_active Ceased
- 2017-05-29 SG SG11201810531TA patent/SG11201810531TA/en unknown
- 2017-05-29 LT LTEPPCT/EP2017/062841T patent/LT3465207T/lt unknown
- 2017-05-29 HU HUE17725620A patent/HUE056359T2/hu unknown
- 2017-05-29 AU AU2017272493A patent/AU2017272493B2/en active Active
- 2017-05-29 ES ES17725620T patent/ES2899110T3/es active Active
- 2017-05-29 BR BR112018074856-0A patent/BR112018074856A2/pt not_active Application Discontinuation
- 2017-05-29 PT PT177256203T patent/PT3465207T/pt unknown
- 2017-05-29 PL PL17725620T patent/PL3465207T3/pl unknown
- 2017-05-29 US US16/304,182 patent/US10976310B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| PL3465207T3 (pl) | 2022-01-17 |
| KR20190013999A (ko) | 2019-02-11 |
| AU2017272493A1 (en) | 2018-12-20 |
| DK3465207T3 (da) | 2021-11-15 |
| HUE056359T2 (hu) | 2022-02-28 |
| US10976310B2 (en) | 2021-04-13 |
| BR112018074856A2 (pt) | 2019-03-06 |
| KR102346785B1 (ko) | 2022-01-04 |
| ES2899110T3 (es) | 2022-03-10 |
| CN109219750B (zh) | 2022-05-31 |
| AU2017272493B2 (en) | 2021-07-22 |
| US20190361012A1 (en) | 2019-11-28 |
| LT3465207T (lt) | 2021-12-10 |
| CA3025711A1 (en) | 2017-12-07 |
| EP3465207A1 (en) | 2019-04-10 |
| SI3465207T1 (sl) | 2022-01-31 |
| EP3465207B1 (en) | 2021-09-01 |
| WO2017207460A1 (en) | 2017-12-07 |
| CN109219750A (zh) | 2019-01-15 |
| PT3465207T (pt) | 2021-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201810531TA (en) | Ligand identification by co-fractionation | |
| SG11201906341XA (en) | Improved serum albumin binders | |
| SG11201906264YA (en) | Improved serum albumin binders | |
| SG11201804510PA (en) | Biparatopic polypeptides antagonizing wnt signaling in tumor cells | |
| SG11201810933QA (en) | Anti-c5 antibodies and uses thereof | |
| SG11201909154SA (en) | Bispecific antibodies specifically binding to pd1 and lag3 | |
| SG11201909914RA (en) | Compositions and methods for improving sample identification in indexed nucleic acid libraries | |
| SG11201805950UA (en) | Self-assembled nanostructures and separation membranes comprising aquaporin water channels and methods of making and using them | |
| SG11201903693QA (en) | Polypeptide variants and uses thereof | |
| SG11201903857UA (en) | Antibodies to pd-1 and uses thereof | |
| SG11201810149VA (en) | Anti hla-g specific antibodies | |
| SG11201806190TA (en) | Isotachophoresis for purification of nucleic acids | |
| SG11201901834WA (en) | Micrornas as biomarkers for endometriosis | |
| SG11201807636XA (en) | Process for producing a polyacrylamide solution with increased viscosity | |
| SG11201811336TA (en) | Method for producing an electrode catalyst from a perovskite metal oxide | |
| SG11201908154RA (en) | Improved immunogenicity assays | |
| SG11201903153PA (en) | Metal recovery process | |
| SG11201910195WA (en) | Methods for trapping and barcoding discrete biological units in hydrogel | |
| SG11201900618WA (en) | Permanently polarized hydroxyapatite, a process for its manufacture and uses thereof | |
| SG11201907927SA (en) | Binding molecules that specifically bind to tau | |
| SG11201900636WA (en) | Aluminum alloy products, and methods of making the same | |
| SG11201809413RA (en) | Detection of chromosome interaction relevant to breast cancer | |
| SG11201809685XA (en) | A method of enhancing the performance of chromatography methods for purification of proteins | |
| SG11201809903WA (en) | Method for purification and activation of botulinum neurotoxin | |
| SG11201807382RA (en) | A single- or multiple component composition for producing a hydrogel |